🚀 VC round data is live in beta, check it out!
Torrent Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Torrent Pharmaceuticals and similar public comparables like BridgeBio Pharma, Ascendis Pharma, Kelun-Biotech, Regencell Bioscience and more.
Torrent Pharmaceuticals Overview
About Torrent Pharmaceuticals
Torrent Pharmaceuticals Ltd is a drug manufacturing company with a focus on the cardiovascular, central nervous system, Vitamins Minerals Nutrients (VMN), and gastrointestinal therapeutic areas. It operates through the Generic Formulation Business segment. Geographically, the business activities are carried out across Indian and International markets. Maximum revenue for the company is generated from its operations in India.
Founded
1972
HQ
Employees
17.3K
Website
Sectors
Financials (LTM)
EV
$15B
Torrent Pharmaceuticals Financials
Torrent Pharmaceuticals reported last 12-month revenue of $1B and EBITDA of $476M.
In the same LTM period, Torrent Pharmaceuticals generated $1B in gross profit, $476M in EBITDA, and $260M in net income.
Revenue (LTM)
Torrent Pharmaceuticals P&L
In the most recent fiscal year, Torrent Pharmaceuticals reported revenue of $1B and EBITDA of $437M.
Torrent Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $905M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $476M | XXX | $437M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| Net Profit | $260M | XXX | $229M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | — | — | $263M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Torrent Pharmaceuticals Stock Performance
Torrent Pharmaceuticals has current market cap of $15B, and enterprise value of $15B.
Market Cap Evolution
Torrent Pharmaceuticals' stock price is $44.64.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15B | $15B | 1.4% | XXX | XXX | XXX | $0.68 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTorrent Pharmaceuticals Valuation Multiples
Torrent Pharmaceuticals trades at 10.6x EV/Revenue multiple, and 32.1x EV/EBITDA.
EV / Revenue (LTM)
Torrent Pharmaceuticals Financial Valuation Multiples
As of April 16, 2026, Torrent Pharmaceuticals has market cap of $15B and EV of $15B.
Equity research analysts estimate Torrent Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Torrent Pharmaceuticals has a P/E ratio of 58.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15B | XXX | $15B | XXX | XXX | XXX |
| EV (current) | $15B | XXX | $15B | XXX | XXX | XXX |
| EV/Revenue | 10.6x | XXX | 11.4x | XXX | XXX | XXX |
| EV/EBITDA | 32.1x | XXX | 35.0x | XXX | XXX | XXX |
| EV/EBIT | 40.5x | XXX | 44.6x | XXX | XXX | XXX |
| EV/Gross Profit | 14.0x | XXX | 16.9x | XXX | XXX | XXX |
| P/E | 58.1x | XXX | 66.0x | XXX | XXX | XXX |
| EV/FCF | (48.0x) | XXX | 66.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Torrent Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Torrent Pharmaceuticals Margins & Growth Rates
Torrent Pharmaceuticals' revenue in the last 12 month grew by 12%.
Torrent Pharmaceuticals' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Torrent Pharmaceuticals' rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Torrent Pharmaceuticals' rule of X is 69% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Torrent Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 69% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Torrent Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Torrent Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| BridgeBio Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascendis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Kelun-Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Regencell Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Sobi | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Torrent Pharmaceuticals M&A Activity
Torrent Pharmaceuticals acquired XXX companies to date.
Last acquisition by Torrent Pharmaceuticals was on XXXXXXXX, XXXXX. Torrent Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Torrent Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTorrent Pharmaceuticals Investment Activity
Torrent Pharmaceuticals invested in XXX companies to date.
Torrent Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Torrent Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Torrent Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Torrent Pharmaceuticals
| When was Torrent Pharmaceuticals founded? | Torrent Pharmaceuticals was founded in 1972. |
| Where is Torrent Pharmaceuticals headquartered? | Torrent Pharmaceuticals is headquartered in India. |
| How many employees does Torrent Pharmaceuticals have? | As of today, Torrent Pharmaceuticals has over 17K employees. |
| Is Torrent Pharmaceuticals publicly listed? | Yes, Torrent Pharmaceuticals is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Torrent Pharmaceuticals? | Torrent Pharmaceuticals trades under TORNTPHARM ticker. |
| When did Torrent Pharmaceuticals go public? | Torrent Pharmaceuticals went public in 2002. |
| Who are competitors of Torrent Pharmaceuticals? | Torrent Pharmaceuticals main competitors are BridgeBio Pharma, Ascendis Pharma, Kelun-Biotech, Regencell Bioscience. |
| What is the current market cap of Torrent Pharmaceuticals? | Torrent Pharmaceuticals' current market cap is $15B. |
| What is the current revenue of Torrent Pharmaceuticals? | Torrent Pharmaceuticals' last 12 months revenue is $1B. |
| What is the current revenue growth of Torrent Pharmaceuticals? | Torrent Pharmaceuticals revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Torrent Pharmaceuticals? | Current revenue multiple of Torrent Pharmaceuticals is 10.6x. |
| Is Torrent Pharmaceuticals profitable? | Yes, Torrent Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Torrent Pharmaceuticals? | Torrent Pharmaceuticals' last 12 months EBITDA is $476M. |
| What is Torrent Pharmaceuticals' EBITDA margin? | Torrent Pharmaceuticals' last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Torrent Pharmaceuticals? | Current EBITDA multiple of Torrent Pharmaceuticals is 32.1x. |
| What is the current FCF of Torrent Pharmaceuticals? | Torrent Pharmaceuticals' last 12 months FCF is ($319M). |
| What is Torrent Pharmaceuticals' FCF margin? | Torrent Pharmaceuticals' last 12 months FCF margin is (22%). |
| What is the current EV/FCF multiple of Torrent Pharmaceuticals? | Current FCF multiple of Torrent Pharmaceuticals is (48.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.